HUE045460T2 - Fenotiazin vegyületek enyhe kognitív zavar kezelésére - Google Patents
Fenotiazin vegyületek enyhe kognitív zavar kezeléséreInfo
- Publication number
- HUE045460T2 HUE045460T2 HUE08762390A HUE08762390A HUE045460T2 HU E045460 T2 HUE045460 T2 HU E045460T2 HU E08762390 A HUE08762390 A HU E08762390A HU E08762390 A HUE08762390 A HU E08762390A HU E045460 T2 HUE045460 T2 HU E045460T2
- Authority
- HU
- Hungary
- Prior art keywords
- cognitive impairment
- mild cognitive
- treating mild
- phenothiazine compounds
- phenothiazine
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title 1
- 208000027061 mild cognitive impairment Diseases 0.000 title 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94500607P | 2007-06-19 | 2007-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE045460T2 true HUE045460T2 (hu) | 2019-12-30 |
Family
ID=39943003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE08762390A HUE045460T2 (hu) | 2007-06-19 | 2008-06-17 | Fenotiazin vegyületek enyhe kognitív zavar kezelésére |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9211294B2 (enExample) |
| EP (1) | EP2167095B1 (enExample) |
| JP (1) | JP5725605B2 (enExample) |
| CN (1) | CN101820884B (enExample) |
| AU (1) | AU2008265045B2 (enExample) |
| BR (1) | BRPI0813670A2 (enExample) |
| CA (1) | CA2690746C (enExample) |
| DK (1) | DK2167095T3 (enExample) |
| ES (1) | ES2739546T3 (enExample) |
| HR (1) | HRP20191513T1 (enExample) |
| HU (1) | HUE045460T2 (enExample) |
| MY (1) | MY177001A (enExample) |
| PL (1) | PL2167095T3 (enExample) |
| PT (1) | PT2167095T (enExample) |
| SI (1) | SI2167095T1 (enExample) |
| WO (1) | WO2008155533A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007008550D1 (de) | 2006-03-29 | 2010-09-30 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung |
| MY161656A (en) * | 2007-10-03 | 2017-04-28 | Wista Lab Ltd | Therapeutic use of diaminophenothiazines |
| US8785434B2 (en) | 2010-04-30 | 2014-07-22 | Prosetta Antiviral Inc. | Antiviral compounds |
| US8828986B2 (en) | 2011-04-20 | 2014-09-09 | Prosetta Antiviral Inc. | Antiviral compounds |
| RS55237B1 (sr) | 2011-02-11 | 2017-02-28 | Wis Ta Laboratories Ltd | Fenotiazin diaminijum soli i njihova primena |
| PL3686181T3 (pl) * | 2013-01-30 | 2024-11-04 | Ecolab Usa Inc. | Zmiatacze siarkowodoru |
| US10304006B2 (en) * | 2013-02-15 | 2019-05-28 | The Charles Stark Draper Laboratory, Inc. | Method for integrating and fusing heterogeneous data types to perform predictive analysis |
| CA2976776C (en) | 2015-02-17 | 2023-06-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
| KR102475825B1 (ko) * | 2016-07-25 | 2022-12-08 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| EP4364801B1 (en) * | 2018-07-26 | 2025-11-12 | TauRx Therapeutics Management Ltd. | Optimised dosage of diaminophenothiazines in populations |
| MY209608A (en) * | 2019-04-10 | 2025-07-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Adaptive neurological testing method |
| GB201909454D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Lab Ltd | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| KR20250154422A (ko) | 2023-03-03 | 2025-10-28 | 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 | 미세혈관 뇌질환 치료를 위한 디아미노페노티아진 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| WO2004087160A1 (en) * | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| EP2322517B1 (en) * | 2004-09-23 | 2019-04-24 | WisTa Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| WO2006091728A2 (en) * | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| AU2007231126B2 (en) | 2006-03-29 | 2012-11-01 | TauRx Therapeutics Management Ltd | Inhibitors of protein aggregation |
| EP2853293B1 (en) | 2006-03-29 | 2017-11-22 | WisTa Laboratories Ltd. | Thioninium compounds and their use |
| DE602007008550D1 (de) * | 2006-03-29 | 2010-09-30 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung |
| US7956183B2 (en) | 2006-07-11 | 2011-06-07 | Wista Laboratories Ltd. | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
-
2008
- 2008-06-17 PL PL08762390T patent/PL2167095T3/pl unknown
- 2008-06-17 CN CN2008801031955A patent/CN101820884B/zh active Active
- 2008-06-17 MY MYPI20095255A patent/MY177001A/en unknown
- 2008-06-17 HR HRP20191513 patent/HRP20191513T1/hr unknown
- 2008-06-17 BR BRPI0813670-0A2A patent/BRPI0813670A2/pt not_active Application Discontinuation
- 2008-06-17 ES ES08762390T patent/ES2739546T3/es active Active
- 2008-06-17 CA CA2690746A patent/CA2690746C/en active Active
- 2008-06-17 AU AU2008265045A patent/AU2008265045B2/en active Active
- 2008-06-17 HU HUE08762390A patent/HUE045460T2/hu unknown
- 2008-06-17 WO PCT/GB2008/002066 patent/WO2008155533A2/en not_active Ceased
- 2008-06-17 US US12/665,608 patent/US9211294B2/en active Active
- 2008-06-17 DK DK08762390.6T patent/DK2167095T3/da active
- 2008-06-17 PT PT08762390T patent/PT2167095T/pt unknown
- 2008-06-17 EP EP08762390.6A patent/EP2167095B1/en active Active
- 2008-06-17 SI SI200832080T patent/SI2167095T1/sl unknown
- 2008-06-17 JP JP2010512761A patent/JP5725605B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI2167095T1 (sl) | 2019-09-30 |
| PT2167095T (pt) | 2019-08-06 |
| WO2008155533A2 (en) | 2008-12-24 |
| AU2008265045B2 (en) | 2014-02-27 |
| BRPI0813670A2 (pt) | 2014-12-30 |
| AU2008265045A1 (en) | 2008-12-24 |
| US9211294B2 (en) | 2015-12-15 |
| ES2739546T3 (es) | 2020-01-31 |
| DK2167095T3 (da) | 2019-07-29 |
| EP2167095B1 (en) | 2019-05-29 |
| HRP20191513T1 (hr) | 2019-11-29 |
| CA2690746A1 (en) | 2008-12-24 |
| WO2008155533A3 (en) | 2009-02-19 |
| CA2690746C (en) | 2018-01-02 |
| PL2167095T3 (pl) | 2019-11-29 |
| JP5725605B2 (ja) | 2015-05-27 |
| MY177001A (en) | 2020-09-01 |
| CN101820884A (zh) | 2010-09-01 |
| US20100184752A1 (en) | 2010-07-22 |
| JP2010530403A (ja) | 2010-09-09 |
| EP2167095A2 (en) | 2010-03-31 |
| CN101820884B (zh) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2167095T3 (pl) | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych | |
| EP2504011A4 (en) | METHOD FOR TREATING EASY COGNITIVE IMPAIRMENT | |
| IL209895A0 (en) | Compounds for treating beta-amyloidoses | |
| GB2445465B (en) | Process for waste treatment | |
| IL198851A0 (en) | Methods for treating hypercholesterolemia | |
| EP2079414A4 (en) | SYSTEM FOR CHEMOHYPER THERMAL TREATMENT | |
| AP2009004746A0 (en) | Process for prepaiIrng diaminophenothiazinium compounds | |
| PL3028716T3 (pl) | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów | |
| EP1877055A4 (en) | 4-AMINOQUINOLINE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASE CONDITIONS | |
| ZA200809528B (en) | Treatment for depressive disorders | |
| PL2001892T3 (pl) | Imidazolotiazolowe związki do leczenia chorób proliferacyjnych | |
| AU2007288337A8 (en) | Compounds for treating proliferative disorders | |
| IL193410A0 (en) | Purification method for effluent | |
| ZA200809527B (en) | Treatment for depressive disorders | |
| IL213398A0 (en) | Compounds for treating cancer | |
| IL204728A0 (en) | Methods and compounds for treating retinol-related diseases | |
| IL198856A0 (en) | Compounds useful for treating neurodegenerative disorders | |
| GB0810364D0 (en) | Improved effluent treatment | |
| PT2481407T (pt) | Compostos para utilização no tratamento de distúrbios cognitivos | |
| ZA201002993B (en) | Novel compounds for fabric treatment | |
| IL209947A (en) | Compounds for the treatment of corneal inflammation | |
| GB0707556D0 (en) | Treatment for cancer | |
| ZA200901672B (en) | Compounds for treating proliferative disorders | |
| IL205752A0 (en) | Octahydroquinolizines for antidiabetic treatment | |
| PL2043792T3 (pl) | System do obróbki ciągłej |